Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, COLL is expected to report 3Q20 income of $ 0.22 per share from revenue of $ 77.43 million.
For the full year, analysts anticipate top line of $ 309.77 million, while looking forward to income of $ 0.73 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 300.00 million ~ $ 320.00 million
Click Here For More Historical Outlooks Of Collegium Pharmaceutical, Inc.
Previous Quarter Performance
Collegium Pharmaceutical, Inc. outlined income for the second quarter of $ 0.23 per share, from the revenue of $ 78.06 million. Wall street analysts are predicting, COLL to report 2Q20 income of $ 0.20 per share from revenue of $ 74.40 million. The bottom line results beat street analysts by $ 0.03 or 15.00 percent, at the same time, top line results outshined analysts by $ 3.66 million or 4.92 percent.
Stock Performance
Shares of Collegium Pharmaceutical, Inc. traded up $ 0.57 or 3.06 percent on Wednesday, reaching $ 19.22 with volume of 194.10 thousand shares. Collegium Pharmaceutical, Inc. has traded high as $ 19.31 and has cracked $ 18.58 on the downward trend
The closing price of $ 19.22, representing a 43.46 % increase from the 52 week low of $ 13.00 and a 27.12 % decrease over the 52 week high of $ 25.59.
The company has a market capital of $ 663.58 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Collegium Pharmaceutical, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.collegiumpharma.com
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting. The company offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication.
